HYFT Overview

MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd., is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, the Company unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.

Wall Street analysts forecast HYFT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HYFT is5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

MindWalk Holdings Corp revenue for the last quarter amounts to 4.12M USD, increased 53.94

MindWalk Holdings Corp. EPS for the last quarter amounts to -0.07 USD, decreased -22.22

MindWalk Holdings Corp (HYFT) has 0 emplpoyees as of March 03 2026.

Today HYFT has the market capitalization of 53.23M USD.